ACLX Insider Selling: 9 Transactions on April 28, 2026

Insider trading is like watching the captain check the lifeboats before a storm. When executives and directors suddenly sell shares, it sends a signal worth decoding. On April 28, 2026, nine insiders at ACLX (Arcellx, Inc.) filed Form 4 disclosures revealing a coordinated wave of selling activity. The transactions totaled approximately $4.8 million in combined value. Six dispositions and three acquisitions paint a mixed picture of insider confidence. Let’s examine what these filings reveal about the biotech company’s leadership and their market outlook.

The Selling Wave: Directors and Officers Dispose of Stock

On April 28, 2026, six insiders at Arcellx filed Form 4 documents showing dispositions of common stock and stock options. These sales represent the dominant signal in today’s insider activity.

Behbahani Ali’s Common Stock Sale

Director Behbahani Ali disposed of 2,706 shares of common stock through a U-Tender transaction at $115.00 per share, generating $311,190 in proceeds. The U-Tender code indicates a tender offer response, suggesting a structured corporate action rather than open-market selling.

Lubner David Charles’ Significant Disposition

Director Lubner David Charles executed the largest single sale, disposing of 21,659 shares of common stock at $115.00 per share for $2,490,785. This substantial transaction also used the U-Tender mechanism, indicating both insiders participated in the same tender offer event.

Stock Option Returns by Multiple Directors

Directors Myers Kristin, Patel Kavita, Galligan Andrew H, and Ware Olivia C all filed D-Return transactions, disposing of stock options at varying prices. Myers returned 16,829 options at $69.87 per share ($1,175,842). Patel returned 11,459 options at $37.94 per share ($434,754). Galligan returned 1,784 options at $63.68 per share ($113,605). Ware returned 36,806 options at $7.61 per share ($280,094). The D-Return code means these options were returned to the company, typically upon expiration or forfeiture.

The Acquisition Side: Executive Equity Awards

While six insiders sold, three executives acquired performance-based restricted stock units (RSUs) on the same date. These awards represent compensation rather than market purchases.

Elghandour Rami’s Major RSU Award

Rami Elghandour, serving as both Director and Officer, received an A-Award (grant) of 284,388 performance-based RSUs on April 28, 2026. This substantial equity grant reflects his senior leadership role. The A-Award transaction type indicates a new grant with no purchase price, typical of executive compensation packages.

Chief Medical Officer Heery’s RSU Grant

Christopher Heery, Chief Medical Officer, acquired 45,138 performance-based RSUs through an A-Award transaction. This grant aligns with his executive compensation structure and reflects the company’s commitment to retaining medical leadership.

Chief Financial Officer Gilson’s Equity Compensation

Michelle Gilson, Chief Financial Officer, received 59,028 performance-based RSUs as an A-Award grant. Her acquisition represents standard executive equity compensation tied to performance metrics. These three acquisitions total 388,554 RSUs granted to senior management.

What These Insider Transactions Mean

The April 28 filing activity reveals a complex insider picture at Arcellx. The SEC filing from Behbahani Ali and the parallel U-Tender transactions suggest a structured corporate event, not panic selling. Directors participating in a tender offer typically indicates confidence in the company’s valuation.

Mixed Signals on Leadership Confidence

The simultaneous granting of large RSU packages to three executives (Elghandour, Heery, and Gilson) suggests the board is rewarding and retaining key talent. Performance-based RSUs tie compensation to future results, aligning executive interests with shareholder value. However, the return of stock options by four directors could indicate those grants were underwater or reaching expiration.

Tender Offer Context

The U-Tender transactions by Behbahani and Lubner suggest a formal tender offer process. This structured approach differs from open-market sales and typically reflects a company-initiated buyback or similar corporate action. The consistent $115 price point supports this interpretation.

Overall Insider Sentiment

Arcellx’s insider activity on April 28 shows a balanced approach. Leadership is acquiring new equity stakes through RSU grants while disposing of older option grants and participating in a tender offer. This pattern suggests confidence in the company’s direction combined with normal equity management practices. Meyka AI rates ACLX a grade of B, reflecting solid fundamentals and sector positioning.

Transaction Summary and Filing Details

All nine insider transactions were filed on April 28, 2026, using Form 4 disclosures required by SEC regulations. Form 4 filings must be submitted within two business days of the transaction.

Complete Transaction Breakdown

Six dispositions totaled approximately $4,806,269 in value. Three acquisitions involved 388,554 performance-based RSUs with no stated purchase price. The dispositions included two common stock sales ($2,801,975 combined) and four stock option returns ($2,004,295 combined). Transaction types ranged from U-Tender (tender offer participation) to D-Return (option returns) to A-Award (equity grants).

Filing Accessibility

Each insider filed individual Form 4 documents with the SEC. These filings are public records available through the SEC’s EDGAR database. Investors can review detailed transaction information, including exact share counts, prices, and ownership changes. The filings provide transparency into executive and director trading activity at publicly traded companies.

Final Thoughts

Arcellx insiders executed nine transactions on April 28, 2026, totaling approximately $4.8 million in combined activity. Six directors and officers disposed of common stock and stock options while three executives acquired performance-based RSUs as compensation. The dominant signal is selling, but the structured nature of the U-Tender transactions and simultaneous equity grants suggest normal corporate activity rather than loss of confidence. The company’s Meyka Grade of B reflects solid fundamentals. Investors should monitor future insider filings for sustained selling patterns or changes in executive compensation structure.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.